跳至主要内容
临床试验/ISRCTN87656744
ISRCTN87656744已完成3 期

Cerebrolysin as Early add-on to REperfusion therapy and risk of HEmorrhagic Transformation after Ischemic Stroke (CEREHETIS). A prospective randomized active-control multicenter pilot study

State Autonomous Institution of Health Interregional Clinical Diagnostic Center0 个研究点目标入组 341 人开始时间: 2021年2月16日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
341

研究概览

简要总结

2023 Results article in https://pubmed.ncbi.nlm.nih.gov/36973684/ results (added 28/03/2023) 2021 Abstract results in https://doi.org/10.1177/23969873211034932 Results abstract European Stroke Organisation Conference 2021 (added 29/03/2023) 2023 Results article in https://doi.org/10.17116/jnevro202312308260 (added 11/09/2023) 2024 Other publications in https://doi.org/10.3389/fphar.2023.1288718 Post hoc analysis (added 22/01/2024) 2023 Abstract results in https://doi.org/10.1159/000534859 (added 23/01/2024) 2024 Other publications in https://pubmed.ncbi.nlm.nih.gov/38512096/ Post hoc analysis (added 02/04/2024)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Patients with confirmed diagnosis of acute ischemic stroke (AIS)
  • 2. Male or female gender
  • 3. Age =18 years
  • 4. Admission to one of the sites within 4.5 h after the AIS onset
  • 5. Indications for intravenous thrombolytic therapy

排除标准

  • 1. Contraindications for intravenous thrombolytic therapy
  • 2. Contraindications for Cerebrolysin
  • 3. Signs of hemorrhagic transformation or intracranial hemorrhage on the screening CT scan
  • 4. Any other concurrent life-threatening medical condition

研究者

发起方
State Autonomous Institution of Health Interregional Clinical Diagnostic Center

相似试验

Cerebrolysin to prevent intracranial bleeding after... | 临床试验